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Introduction: Many neurodegenerative diseases are characterised by accumulations of misfolded proteins that can
colocalise with chaperone proteins (for example, heat shock protein 27 (HSP27)), which might act as modulators of
protein aggregation.
Methods: The role of HSP27 in the pathogenesis of neurodegenerative disorders such as frontotemporal lobar
degeneration (FTLD), Alzheimer’s disease (AD) and motor neuron disease (MND) was investigated. We used
immunohistochemical and Western blot analysis to determine the distribution and amount of this protein in the
frontal and temporal cortices of diseased and control subjects.
Results: HSP27 immunostaining presented as accumulations of granules within neuronal and glial cell perikarya.
Patients with AD and FTLD were affected more often, and showed greater immunostaining for HSP27, than
patients with MND and controls. In FTLD, there was no association between HSP27 and histological type. The
neuropathological changes of FTLD, AD and MND were not immunoreactive to HSP27. Western blot analysis
revealed higher HSP27 expression in FTLD than in controls, but without qualitative differences in banding patterns.
Conclusions: The pattern of HSP27 immunostaining observed may reflect the extent of ongoing
neurodegeneration in affected brain areas and is not specific to FTLD, AD or MND. It may represent an
accumulation of misfolded, damaged or unwanted proteins, awaiting or undergoing degradation.Introduction
Many neurodegenerative diseases, also termed as protein
conformational diseases [1], are characterised by accumu-
lations of misfolded proteins that often share morpho-
logical and biochemical features and can colocalise with
several other proteins, including various chaperone pro-
teins. The accumulation of misfolded proteins may
adversely affect neuronal connectivity and plasticity
and trigger cell death signalling pathways [2]. These
misfolded proteins include amyloid-β protein (Aβ) and
tau in Alzheimer’s disease (AD); α-synuclein and synphilin
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unless otherwise stated.expanded huntingtin in Huntington’s disease; transactive
response DNA binding protein 43 (TDP-43) and
copper-zinc superoxide dismutase 1 in motor neuron
disease (MND); and tau, TDP-43 and fused in sarcoma
in frontotemporal lobar degeneration (FTLD). These
aggregates may consist of oligomeric complexes of
non-native secondary structures and demonstrate poor
solubility in aqueous or detergent solvents [3]. Chaperone
proteins, such as heat shock proteins (HSPs), play a prime
role in protein homeostasis by binding to substrates at
risk, thereby keeping them in a state competent for either
refolding or degradation [4]. Chaperone proteins have
therefore been implicated as potent modulators of protein
conformational disorders, suppressing toxicity of misfold-
ing proteins and modifying early events in the aggregation
process in a cooperative and sequential manner reminis-
cent of their functions in de novo protein folding [5,6].
HSP27, also known as HSPB1, is one of the best studied
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native proteins, and plays a critical role in stabilisation
of the cytoskeleton through interactions with several cyto-
skeletal components, such as actin, intermediate filaments
and microtubules [7]. Normally, when functioning as a
molecular chaperone, HSP27 can bind non-native sub-
strates in an ATP-independent manner, which is quite dif-
ferent from most HSPs [8]. However, for substrate release,
it requires the help of ATP-dependent chaperone proteins,
such as HSP70 and HSP104 [9]. Additionally, HSP27 can
exhibit a number of cytoprotective properties in cell culture,
attenuating apoptosis through interaction with proapoptotic
proteins such as Daxx, cytosolic cytochrome c and caspase
3, as well as suppressing aggregate formation [10,11].
HSP27 has been implicated in various neurodegenera-
tive diseases. For example, a highly induced expression of
HSP27 has been reported in the brains of aged persons
and of patients with AD, being present in proliferating
astrocytes, especially in AD in those areas rich in senile
(Aβ) plaques. Neurofibrillary tangles, Hirano bodies and
some hippocampal neurons have also been reported to
be HSP27-immunoreactive. However, in control brains,
HSP27 immunoreactivity was restricted to blood vessels
and to occasional astrocytes in the white matter. Simi-
larly, patients with other types of dementia (Parkinson–
dementia complex, multi-infarct dementia and normal
pressure hydrocephalus) showed less expression of HSP27
in reactive astrocytes than that in AD, but more than that in
controls. Occasional immunoreactive HSP27 astrocytes have
also been reported to be present in Parkinson disease [12].
Although the physiological relationship between HSP27
and misfolded proteins in neurodegenerative diseases has
been studied intensively in vivo and in vitro, any potential
role of HSP27 in the pathogenesis of neurodegenerative
diseases, and especially FTLD, is still incompletely under-
stood. The principal aim of this study was to investigate
the possible role of HSP27 in the pathogenesis of FTLD.
This was achieved by comparing the distribution and
amount of HSP27 in FTLD, AD, MND and control groups
by immunohistochemistry, and by characterising bio-
chemical changes using Western blotting.
Methods
Patients
The study group comprised 175 patients, composed of
72 patients with FTLD, 46 with AD, 25 with MND and
32 controls (see Table 1 for demographic characteristics).
Patients with FTLD fulfilled the Lund-Manchester criteria
[13] for sporadic or familial FTLD and their characteristics
were consistent with recent consensus criteria [14]. All had
been longitudinally assessed within the Cerebral Function
Unit, Salford Royal Hospital, with the Manchester Neuro-
psychological Test Battery. Data collected on each patient
included sex, age at diagnosis and at death, and clinicaldiagnosis. The clinical diagnosis was confirmed at autopsy
[15]. The FTLD patients were histologically classified
according to the harmonised classification system for
FTLD-TDP [16] into FTLD-TDP type A, FTLD-TDP
type B and FTLD-TDP type C (Table 1). The diagnosis
of clinical MND (in patients with or without FTLD) was
in keeping with El Escorial criteria [17]. Diagnosis of
possible or probable AD was made in accordance with
the National Institute of Neurological and Communicative
Disorders and Stroke–Alzheimer’s Disease and Related
Disorders Association criteria [18] and was confirmed
pathologically according to Consortium to Establish a
Registry for Alzheimer’s disease criteria [19]. Control
subjects were obtained from a longitudinal ageing cohort
of elderly people without clinical symptoms of dementia.
All brains were drawn from the Manchester Brain Bank
and had been obtained with full ethical permission of the
Manchester Brain Bank Management Committee under
Tissue Bank Ethical Agreement 08 conferred by Newcastle
and North Tyneside 1 Research Ethics Committee follow-
ing appropriate consenting procedures by the next of kin.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections (6 μm) of
frontal cortex (Brodmann areas 8/9 (BA8/9)) and/or
temporal cortex (BA21/22) with hippocampus (where
available; see Table 1) were immunostained for HSP27
using a commercially available rabbit polyclonal HSP27
antibody (ab5579; Abcam, Cambridge, UK). A standard
immunostaining procedure was followed [20,21]. Briefly,
all deparaffinised sections underwent antigen retrieval in
0.1 M citrate buffer, pH 6.0, by microwave heating for
10 minutes. To quench endogenous peroxidase activity,
slides were incubated in 0.3% hydrogen peroxide in
methanol for 30 minutes. Sections were then incubated
overnight (at 4°C) in a diluted blocking serum (normal
goat serum) to mask nonspecific binding sites. This
was followed by 1-hour immunostaining with primary
polyclonal HSP27 antibody diluted to 1:500. Following
three 5-minute washes in phosphate-buffered saline,
incubations in biotinylated secondary antibody and
avidin–biotin complex were performed for 30 minutes
each using a VECTASTAIN ABC kit (Vector Laboratories,
Peterborough, UK), The immunoreaction was visualised
using 3,3′-diaminobenzidine (Sigma, Poole, Dorset, UK).
Sections were lightly counterstained with haematoxylin,
dehydrated sequentially and mounted with coverslips
using DePeX mounting medium. Further sections were
immunostained for LAMP1 (rabbit polyclonal antibody
AP1823a; Abgent, San Diego, CA, USA), LCA3 (rabbit
polyclonal antibody L8793; Sigma, St Louis, MO, USA),
p62 (p62-lck ligand, rabbit polyclonal antibody; BD Bio-
sciences, Oxford, UK) and ubiquitin (rabbit polyclonal
antibody Z0458; Dako Cytomation, Ely, UK), employing
Table 1 Demographic detailsa
Group (n) M/F, n
(missing data)




Controls (32) 14/18 72.0 ± 21.0 19 32 31
AD (46) 23/23 72.0 ± 6.0 46 41 41
MND (25) 20/5 64.3 ± 12.0 17 25 24
FTLD (72) 41/31 65.6 ± 9.1 71 66 60
FTLD-tau (31) 14/14 (3) 67.2 ± 9.6 31 25 25
MAPT (5) 2/3 62.2 ± 5.4 5 4 4
Pick (26) 12/11 (3) 68.3 ± 10.1 26 21 21
FTLD-TDP (41) 26/15 64.7 ± 8.7 40 41 35
Type A (17) 8/9 68.7 ± 4.2 17 17 14
Type B (14) 12/2 58.3 ± 9.0 13 14 12
Type C (10) 6/4 66.5 ± 9.4 10 10 9
aAD, Alzheimer’s disease; FTLD, Frontotemporal lobar degeneration; FTLD-MAPT, Frontotemporal lobar degeneration with mutations in the microtubule-associated
protein tau; MND, Motor neuron disease; FTLD-tau Pick, Frontotemporal lobar degeneration tau with Pick bodies; TDP, Transactive response DNA binding protein
43 proteinopathy (subtypes A, B and C according to Mackenzie et al. [16]).
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Pathological assessment
The degree and distribution of HSP27 immunostaining in
both white matter and grey matter were scored semiquan-
titatively in temporal cortex and hippocampus, and/or
frontal cortex, on a 5-point scale (0 = absent; 1 = rare;
2 = mild; 3 = moderate; 4 = severe) using a Leica DMR
microscope (×200 magnification, DC 300 F, 10447115;
Leica Microsystems, Milton Keynes, UK). The examiner
(XK) was blinded to clinical and pathological diagnosis, as
well as to the results of the initial scoring of sections,
when reexamining the series for a second and third time.
Intraclass correlation coefficient and interrater reliability
(Cohen’s κ) testing were used to analyse the consistency of
scoring over the three assessments. The results showed
that there was substantial agreement for ratings per-
formed at each time and for each area (Tables 2 and 3).
Statistical analysis
All data were analysed using appropriate parametric and
nonparametric statistical tests with the SPSS for Windows
statistical software package (release 16.0; IBM SPSS,
Chicago, IL, USA). In immunohistochemical analysis,
the frequency of immunopositive or immunonegative
cases in different brain regions between different groups
was assessed using Pearson’s χ2 test. The severity of
HSP27 immunostaining in different brain regions between
different groups was analysed using a nonparametric
Kruskal-Wallis test with a post hoc Mann-Whitney test.
To guard against false-positive results, given the high
number of statistical tests employed, only P-values ≤0.01
were considered significant.Western blot analysis
Brain tissues from five patients were studied (Table 4).
Clinically, three patients had been diagnosed with various
histological and genetic forms of FTLD. Two cases served
as controls, one without any significant pathology and one
with mild AD-type changes. Fresh-frozen frontal cortex
tissue was used for sequential extraction of proteins with
specific buffers. Sequential extracts of proteins are pro-
duced after several protein preparation steps, including
whole-cell lysate and other fractions—low salt fraction,
Triton X-100 fraction, sarkosyl fraction and urea fraction.
These fractions represent a series containing a decreasing
solubility of (potentially interesting) proteins.
Using an adapted protocol [22], sequential fractions
were examined by Western blotting for HSP27. Equal
volumes (25 μl) of diluted fractions from different samples
and 6-μl molecular weight marker/ladder were condensed
by 5% stacking gel and resolved by 10% SDS-PAGE. Elec-
trophoresis was performed at around 120 V for 60 minutes
using a PowerPac Basic power supply (Bio-Rad Laborator-
ies, Hercules, CA, USA). Once the blue line produced by
loading buffer (2× Laemmli sample buffer) had reached
the bottom plastic plate, the electrophoresis was stopped.
The proteins on the gel were then transferred to
nitrocellulose membranes (Amersham Hybond-ECL;
GE Healthcare Life Sciences, Little Chalfont, UK) via
a ‘semidry’ method (Trans-Blot SD Semi-Dry Transfer
Cell; Bio-Rad Laboratories), which employs a PowerPac
HC Power Supply (Bio-Rad Laboratories) running at 15 V
for 1 hour. Following transfer, membranes were blocked
with Tris-buffered saline containing 3% powered milk for
20 to 60 minutes at room temperature and then probed
with rabbit polyclonal HSP27 antibody (ab5579; Abcam),
which was diluted to 1:3,000 in 3% bovine serum albumin
Table 2 Analysis of assessment scores by intraclass correlation coefficientsa
1st vs 2nd assessments 1st vs 3rd assessments 2nd vs 3rd assessments 1st vs 2nd vs 3rd assessments
Neurons
ICC 0.874 0.815 0.854 0.892
P-value 0.000 0.000 0.000 0.000
Grey matter glial cells
ICC 0.930 0.933 0.935 0.954
P-value 0.000 0.000 0.000 0.000
White matter glial cells
ICC 0.958 0.928 0.935 0.960
P-value 0.000 0.000 0.000 0.000
aICC, Intraclass correlation coefficient. Results with perfect agreement (>0.8) are in boldface.
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antibodies were detected with horseradish peroxidase–
conjugated goat anti-rabbit immunoglobulin G (sc-2004,
1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
and immunoreactive proteins on the blots were revealed
by ECL Plus Western blotting detection reagent ECL
Imager system (Thermo Scientific, Rockford, IL USA).
Results
Cytological observations
In all cases, HSP27 immunoreactivity was seen in the
form of clusters of small or coarse granules within the
cytoplasm of neurons and glial cells. This pattern of
immunostaining was qualitatively similar in all cases,
irrespective of diagnosis, though the severity of changes
varied from case to case between diagnostic categories
and within each diagnostic category.
In all patients with FTLD and AD (Figures 1 and 2),
there were numerous intensely immunostained, HSP27-
positive granules in the cytoplasm of pyramidal neurons
of the cerebral cortex, along with abundant diffuse clus-
ters of similar granules within glial cells in both grey and
white matter regions. Such changes were particularlyTable 3 Analysis of assessment scores by interrater reliability




Grey matter glial cells
Cohen’s κ 0.444
P-value 0.000
White matter glial cells
Cohen’s κ 0.645
P-value 0.000
Results with substantial agreement (0.61 to 0.80) are in boldface.severe in cells of the dentate gyrus and the CA4 region
of the hippocampus, Similar, though less severe, changes
were seen in these same brain areas in patients with
MND and in control subjects.
However, there was no HSP 27 immunostaining of senile
plaques or neurofibrillary tangles within the frontal and
temporal cortices and the hippocampus in patients with
AD, nor was there HSP 27 immunostaining of Pick bodies
in patients with FTLD-tau, or TDP- 43 immunoreactive
neuronal cytoplasmic inclusions in patients with F TLD-TDP,
or MND (not shown).
By immunostaining with LAMP1 antibody, we detected
granular structures in neurons and glial cells that were
similar in appearance to those visualised by HSP27 immu-
nostaining. However, immunostaining with LCA3 anti-
body failed to reveal any granular structures or staining
patterns similar to those detected with HSP27.
Semiquantitative findings
The proportion of cases showing HSP27 immunoreactive
neurons and/or glial cells in the different brain regions
analysed (irrespective of the intensity of staining of







Table 4 Cases assessed in Western blot analysisa
Case Onset, yr Death, yr Duration, yr Clinical diagnosis Pathological diagnosis
1 43 45 2 FTD +MND FTLD-TDP B
2 52 65 13 FTD FTLD-MAPT
3 63 74 11 FTD FTLD-Pick
4 na 80 na Normal None
5 na 82 na Normal Mild AD
aAD, Alzheimer’s disease; FTD, Frontotemporal dementia; FTLD, Frontotemporal lobar degeneration; FTLD-Pick, Frontotemporal lobar degeneration tau with Pick
bodies; FTLD-MAPT, Frontotemporal lobar degeneration with mutations in the microtubule-associated protein tau; FTLD-TDP B, Frontotemporal lobar degeneration
with transactive response DNA binding protein subtype B; MND, Motor neuron disease; na, Not applicable.
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egory showing HSP27 immunoreactive neurons and/or
glial cells was highly significantly different between FTLD
(overall), AD, MND and control groups for frontal cortex
(neurons: χ2 = 20.8, P =0.001; glial cells of grey matter:
χ2 = 15.9, P =0.003; glial cells of white matter: χ2 = 28.8,
P =0.000) and temporal cortex (glial cells of grey matter:
χ2 = 15.8, P =0.001; glial cells of white matter: χ2 = 23.0,
P =0.000) and marginally significant for temporal corticalFigure 1 Characteristic HSP27-positive granules in the cytoplasm of n
cases under light microscopy. (A) Temporal cortex. (B) Frontal cortex. (C
hippocampus. (F) Dentate gyrus of hippocampus.neurons (χ2 = 6.8, P =0.080). However, there were no
significant differences between diagnostic groups for
the proportion of cases in each diagnostic category show-
ing HSP27 immunoreactive neurons in hippocampus CA4
(χ2 = 5.0, P =0.170), CA3/2 (χ2 = 6.0, P =0.113), CA1 and
subiculum (χ2 = 6.1, P =0.106) regions or granule cells of
the dentate gyrus (χ2 = 4.1, P =0.251), though glial cells of
hippocampus did show a significant difference between
groups (χ2 = 21.870, P =0.000).eurons and glial cells in different regions of Alzheimer’s disease
) White matter of cortex. (D) CA4 of hippocampus. (E) CA3 of
Figure 2 Characteristic HSP27-positive granules in the cytoplasm of neurons and glial cells of different regions of frontotemporal lobar
degeneration cases under light microscopy. (A) Temporal cortex. (B) Frontal cortex. (C) White matter of cortex. (D) CA4 of hippocampus.
(E) CA3 of hippocampus. (F) Dentate gyrus of hippocampus.
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fected was higher in FTLD subjects than in controls in
all regions (temporal cortex: neurons, P =0.008; glial
cells of grey matter, P =0.039; glial cells of white matter,
P =0.000; frontal cortex: neurons, P =0.000; glial cells of
grey matter, P =0.000; glial cells of white matter: P =0.000;
hippocampus: glial cells of CA4, P =0.000). Similarly, there
was a higher proportion of cases affected in FTLD than
MND in glial cells of both grey matter (P =0.000) and
white matter (P =0.000) of both the frontal and temporal
cortices (P =0.000 in every instance) and for glial cells of
the hippocampus (P =0.000).
There was a significantly higher proportion of cases
affected in FTLD than in AD in respect of glial cells of
both grey matter (P =0.009) and white matter (P =0.002)
of the frontal cortex, and marginally so for glial cells of
the hippocampus (P =0.013). There was a higher propor-
tion of cases affected in AD than in controls for the tem-
poral cortex white matter glial cells (P =0.012) and the
frontal cortex neurons (P =0.009). There were no significantdifferences between MND and control cases in any region,
except for neurons in CA1 and subiculum (P =0.001).
Subgroup analysis between FTLD-tau and FTLD-TDP
groups, between FTLD-MAPT and FTLD-Pick groups,
and between FTLD-TDP A, B and C groups all showed
no significant differences in the frequencies of HSP27-
positive cases, except for comparison between FTLD-
TDP subtypes A, B and C for glial cells in white matter
of the frontal cortex (χ2 = 11.9, P =0.003), where a
higher proportion of FTLD-TDP A cases (P =0.005)
were affected compared to FTLD-TDP C cases.
The severity of HSP27 immunoreactivity in neurons
and glial cells in the different brain regions in all four
diagnostic groups was compared by Kruskal-Wallis test,
with post hoc Mann-Whitney testing where significant.
In general, analysis showed that neurons and glial cells in
patients with AD and FTLD were more severely affected
than patients with MND Q12 and control subjects
(Figure 4). Comparisons of the FTLD (overall), AD, MND
and control groups showed significant differences in the
Figure 3 Proportion of cases with HSP27-positive granules in different brain regions in each group. AD, Alzheimer’s disease; CA1, neurons
of CA1 + subiculum regions of the hippocampus; CA3/2, Neurons of CA3/2 region of the hippocampus; CA4, Neurons of CA4 region of the
hippocampus; FGG, Grey matter glial cells of the frontal cortex; FN, Neurons of the frontal cortex; FTLD, Frontotemporal lobar degeneration; FWG,
White matter glial cells of the frontal cortex; HPDG, Granular cells of the dentate gyrus of the hippocampus; HPG, Glial cells of the hippocampus;
MND, Motor neuron disease; TGG, Grey matter glial cells of the temporal cortex; TN, Neurons of the temporal cortex; TWG, White matter glial cells
of the temporal cortex.
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P =0.013), grey matter glial cells (F(3, 162) =21.7, P =0.000)
and white matter glial cells (F(3, 162) =25.8, P =0.000) of the
temporal cortex, and for neurons (F(3, 151) =18.9, P =0.001),
grey matter glial cells (F(3, 151) =29.2, P =0.000) and white
matter glial cells (F(3, 151) =46.0, P =0.000) of the frontal
cortex. In the hippocampus, there were also significant
differences in the severity of HSP27 rating for neurons of
CA4 (F(3, 154) =17.8, P =0.000) region and for glial cells
(F(3, 154) =14.9, P =0.002) and granule cells of dentate
gyrus (F(3, 154) =11.8, P =0.008).
Post hoc testing showed that there was significantly
greater HSP27 immunostaining of neurons of the tem-
poral cortex in FTLD compared to controls (P =0.016)
and MND (P =0.007) groups, and marginally significantly
greater staining in AD compared to MND (P =0.028).
Similarly, there was significantly greater HSP27 immuno-
staining of glial cells of grey matter of the temporal cortex
in AD compared to controls (P =0.002).
In the frontal cortex, there was significantly greater
HSP27 staining neurons of the frontal cortex in FTLD
(P =0.004) and AD groups (P =0.001) compared to con-
trols. There was also significantly greater HSP27 staining
in glial cells of grey matter in FTLD compared to MND
(P =0.010), and in glial cells of the white matter in FTLD
compared to both MND (P =0.000) and AD (P =0.002)
groups.
In the hippocampus, there was significantly greater
HSP27 staining in CA4 region in the FTLD group
(P =0.000) and the AD group (P =0.002) compared to
controls, and in the FTLD group compared to the MND
group (P =0.009). There was also significantly greaterHSP27 staining in FTLD compared to AD (P =0.030),
control (P =0.009) and MND (P =0.001) for glial cells
of the hippocampus, and for granule cells of dentate
gyrus in FTLD compared to MND (P =0.002) and control
(P =0.007).
However, subgroup analysis between FTLD-tau and
FTLD-TDP groups, between FTLD-MAPT and FTLD-Pick
groups, and between FTLD-TDP type A, B and C
groups, all showed no significant differences in the se-
verity of HSP27 rating values, except for significant dif-
ferences between FTLD-tau and FTLD-TDP groups for
grey matter glial cells of the frontal cortex (P =0.006).
Western blotting
Western blotting of each fraction of the frontal cortex
from the two samples showed two normal bands at
approximately 50 kDa and approximately 25 kDa, re-
spectively (Figures 5D and 5E). Although there was
higher HSP27 expression in FTLD cases than in control
cases, this was without any change in banding patterns
(Figures 5A, 5B and 5C). Where there were matched
samples, there was good correlation between the inten-
sity of staining on Western blots and the severity of
HSP27 immunoreactive changes on immunohistochem-
ical stains (Table 5). There were no obvious differences
in HSP27 expression between the pathological subtypes
in FTLD (Figures 5A, 5B and 5C).
Discussion
Although the physical and physiological relationships
between chaperone proteins, such as HSP27, and mis-
folded proteins has been studied intensively, a role for
Figure 4 Severity of different rating scores of HSP27 staining in different brain regions in each group. AD, Alzheimer’s disease; CA1,
Neurons of the CA1 and subiculum regions of the hippocampus; CA3/2, Neurons of the CA3/2 region of the hippocampus; CA4, Neurons of the
CA4 region of the hippocampus; FGG, Grey matter glial cells of the frontal cortex; FN, Neurons of the frontal cortex; FTLD, Frontotemporal lobar
degeneration; FWG, White matter glial cells of the frontal cortex; HPDG, Granule cells of the dentate gyrus of the hippocampus; HPG, Glial cells of
the hippocampus; MND, Motor neuron disease; TGG, Grey matter glial cells of the temporal cortex; TN, Neurons of the temporal cortex; TWG,
White matter glial cells of the temporal cortex.
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still incompletely understood. In the present study, the
expression of HSP27 in FTLD, AD, MND and normal
controls was analysed through immunohistochemical
staining with HSP27 antibody and Western blotting.
HSP27 is usually induced in response to cellular stress,
but it can also stabilise the actin cytoskeleton, attenuate
apoptosis, participate in cell differentiation and survival
when phosphorylated [23], and promote cell cycle reentry
into the S-phase by facilitating ubiquitination and degrad-
ation of the cell cycle inhibitor p27Kip1 [24]. The affinity of
HSP27 for proteins to be chaperoned is modulated by its
phosphorylation and oligomerisation status [25].
Our present results show that the expression patterns
of HSP27 in these neurodegenerative diseases are quite
different. Patients with FTLD and AD showed numerous
intensely immunostained, HSP27-positive granules in the
cytoplasm of pyramidal neurons of the cerebral cortex,
along with diffuse clusters of similar granules within glial
cells. Such changes were particularly severe in the CA4 re-
gion of the hippocampus and in cells of the dentate gyrus.
Subgroup analysis showed that there were no differences
in the patterns of immunostaining between FTLD-tau and
FTLD-TDP cases. However, in cases of MND and normalcontrols, we found less extensive accumulation of HSP27
immunoreactive granules in these same brain areas.
These observations probably reflect the greater ongoing
neurodegeneration in these brain areas in AD and FTLD
compared to MND.
There have been few previous studies in which investi-
gators have evaluated HSP27 reactivity in neurodegenera-
tive disease, and then only in relationship to AD. To our
knowledge, there have been no such studies in FTLD. In
general, these studies have shown there to be an increase
in expression of HSP27 in AD brain tissue or in immuno-
labelling of pathological structures [12,25-27]. Using a
rabbit anti-HSP27 antiserum raised against a hybrid
protein containing the N-terminal part of the murine
HSP27 (amino acids 1 to 110) and the C-terminal part
of the human HSP27 (amino acids 111 to 208), Renkawek
and co-workers showed a highly induced expression of
HSP27 in many proliferating astrocytes in affected regions
of cerebral cortex, especially in those areas rich in senile
plaques [12]. They also reported neurofibrillary tangles,
Hirano bodies and some hippocampal neurons to be
immunopositive [12]. The expression of HSP27 correlated
with the severity of AD-specific morphological changes and
the duration of dementia [12]. Shimura and co-workers
Figure 5 Immunoblotting of HSP27 in frontal cortex from FTLD and control cases. (A) Frontotemporal lobar degeneration transactive
response DNA binding protein (FTLD-TDP), case 1. (B) FTLD-MAPT case 2. (C) FTLD-Pick case 3. (D) Control case 4. (E) Control case 5. Lane 1:
Whole-cell lysate; lane 2: low salt fraction; lane 3: Triton X-100 fraction; lane 4: sarkosyl fraction; lane 5: urea fraction.
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munoprecipitation of HSP27 with hyperphosphorylated tau
protein from AD brain, but not with nonphosphorylatedtau from normal brain homogenates [25]. However, in an-
other study, a diffuse, rather than granular, HSP27 immu-
nostaining was observed in a subpopulation of astrocytes
Table 5 Semiquantitative rating of immunoblotting of HSP27 and comparison with immunohistochemistrya
Approximately 25-kDa band Approximately 50-kDa band IHC rating scores
Case WL LS TX SARK UF WL LS TX SARK UF F-N F-GG F-WG F-Astro
1 ++++ ++ + ++ +/- +/- +/- - - - 3 3 2 3
2 +++ +++ ++ +++ +++ + ++ + - - 3 3 3 3
3 + +/- - - +/- ++ +++ + - ++ 2 3 4 4
4 +++ ++ + +++ ++ +/- ++ +/- - +/- nd nd nd nd
5 - - - ++ - - +/- - - - 1 1 1 2
a+/++/+++ of bands; +/- very faint bands; - no bands at all; F-Astro, Astrocytes of frontal cortex; F-GG, Grey matter glial cells of frontal cortex; F-N, Neurons of
frontal cortex; F-WG, White matter glial cells of frontal cortex; IHC, Immunohistochemistry; LS, Low salt fraction; nd, not done; SARK, Sarkosyl fraction; TX, Triton
X-100 fraction; UF, Urea fraction; WL, Whole protein fractions.
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http://alzres.com/content/6/9/78and microglial cells associated with senile plaques and
cerebral amyloid angiopathy, but this was not seen in
neurofibrillary tangles in either the neocortex or hippo-
campus [27]. In a biochemical study, Bjorkdahl and col-
leagues reported the expression of HSP27 in AD brain
to be increased (by approximately 20%) in homogenates
from the medial temporal cortex [26]. Moreover, this in-
crease in HSP27 correlated significantly with the ex-
pression levels of the majority of the phosphorylated tau
epitopes, but not with AT270, Alz-50 or AT100 [26].
In the present study, we observed numerous intensely
immunostained, HSP27-positive granules in the cytoplasm
of pyramidal neurons of the cerebral cortex and as diffuse
clusters of similar appearing granules within glial cells,
in both FTLD and AD. However, in AD, there was no
HSP27 immunostaining of senile plaques or neurofibrillary
tangles within the frontal and temporal cortices or within
the hippocampus. The failure to confirm previous findings
[12] (but see [27]) may be partly due to the different
HSP27 antibodies used. In the present study, the anti-
HSP27 antibody used (ab5579; Abcam) is a rabbit poly-
clonal raised against a synthetic peptide, LLRGPSWDPFRC,
corresponding to amino acids 10 to 21 of human HSP27.
It is much more specific than the rabbit anti-HSP27
antiserum raised against a hybrid protein containing
the N-terminal part of the murine Hsp25 (amino acids
1 to 110) and the C-terminal part of the human HSP27
(amino acids 111 to 208) used by Renkawek et al. [12].
Hence, the staining of plaques (amyloid) or tangles
with this latter antibody may represent nonspecific
cross-reactivity, an interpretation consistent with findings
reported by Wilhelmus and colleagues [27], who likewise
failed demonstrate any immunostaining of these struc-
tures with HSP27. Our presently reported observations
that no HSP27 immunostaining was seen in Pick bodies in
patients with FTLD-tau, or in TDP-43 immunoreactive
neuronal cytoplasmic inclusions in patients with FTLD-
TDP or MND, would support this conclusion. Interest-
ingly, in previous studies where HSP27 immunostaining
of astrocytes has been reported [12,27], this has taken the
form of a homogeneous, diffuse cytoplasmic staining ratherthan one with pronounced granularity as demonstrated
here. Again, different antibody specificities may be re-
sponsible, picking up HSP27 proteins either in a different
conformational state or in aggregated forms.
The pattern of HSP27 immunoreactivity in cells may
reflect an activation of protein quality control systems
consequent upon damage to neurons or a response to
the presence of accumulated tau/TDP-43 proteins. It is
increasingly clear that the cooperation of proteolytic
machineries, such as the proteasome and lysosome,
and chaperone systems is required to prevent the ag-
gregation of potentially toxic misfolded proteins. If
such misfolded proteins escape appropriate refolding
by chaperone systems, the proteasome and lysosome
systems will be recruited to degrade them. However, if
the production of such misfolded proteins overwhelms
the capacity of the protein quality control systems,
protein aggregates will form.
Within our control group, there was variability in the
expression of HSP27. In some control subjects similar
(to AD and FTLD), although less intense, HSP27 changes
were present in the cytoplasm of pyramidal neurons of the
cerebral cortex, and again as diffuse clusters of similar
granules within glial cells. Such changes probably reflect
the mild AD-type pathological changes present in such
control subjects. In a recent study of patients with amnes-
tic mild cognitive impairment (aMCI), a transitional stage
between normal ageing and AD, there was a significant
increase (200%) in the expression of HSP27 in the hippo-
campus in the aMCI group compared to controls [28],
which would be consistent with these ‘intermediate’ histo-
logical findings.
It is presently unclear which cellular compartment or
substructure might be associated with HSP27 immuno-
staining. The granularity of the staining suggests a phago-
cytotic location. Consequently, we stained sections in
which there was an abundance of HSP27-immunoreactive
granules with LAMP1 (a lysosomal marker) and LCA3
(a marker of autophagy) antibodies. LAMP1 detected
granular structures in neurons and glia similar to those
detected by HSP27, but none such were demonstrated
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http://alzres.com/content/6/9/78in LCA3 immunostaining. These observations suggest
that HSP27 immunoreaction is possibly associated with
the cells’ lysosomal compartments and may represent
accumulated protein undergoing or awaiting degradation
or the product of a failed degradation process. Nonetheless,
a proteasomal location is also possible, and the pattern of
immunoreactivity could represent proteasomes clogged or
choked with accumulated protein. However, the fact
that the ‘granules’ were not immunostained with either
p62 or ubiquitin antibodies suggests that the HSP27
immunolabelled material does not contain either of
these proteins, which act as molecular ‘flags’ for pro-
teasomal degradation. Therefore, the subcellular local-
isation of HSP27 immunostaining, and its role in the
neurodegenerative cascade, remains uncertain though
may possibly be lysosomal.Conclusions
In this study, we show that there are distinct patterns of
HSP27 immunostaining with respect to different types
of neurons or glial cells in different brain regions in
patients with neurodegenerative disease. In general,
patients with AD and FTLD were more severely affected
than were patients with MND and control subjects;
however, there was no association with FTLD histological
subtype. Moreover, the ‘classic’ neuropathological changes
in FTLD, AD and MND were not immunoreactive to
HSP27, with the lack of HSP27 immunostaining of
‘classic’ pathology suggesting that HSP27 does not play
a direct role in the formation of these structures.
Therefore, HSP27 immunostaining in neurodegenerative
disease likely reflects the extent of ongoing neurodegener-
ation in affected brain areas and is not specific to FTLD,
AD or MND. It may represent an accumulation of
misfolded, damaged or unwanted proteins, waiting for
degradation via proteolytic mechanisms, though the
precise pathway that this might enter, or fail to enter,
for such a purpose remains unclear.
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